

# THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/629,108

Applicants : Kazuo KOYAMA et al.

Filed : July 28, 2003

For : BENZYLAMINE ANALOGUES

Art Unit : 1626

Examiner : Dr. Taofiq A. SOLOLA

Docket No. : 03338CIP/HG

Customer No.: 01933

Confirm. No.: 6344

### INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313

## MAIL STOP AMENDMENT

#### SIR:

Submitted concomitantly herewith are the following:

- (1) Copies of the publications cited in the AMENDMENT UNDER 37 CFR 1.111 filed concomitantly herewith;
- (2) A copy of Fernandez et al., <u>Movement Disorders</u>, 15, 173-176, (2000);
- (3) An English-language translation of WO 96/22276 (the Japanese language document for WO 96/22276 was submitted with the INFORMATION DISCLOSURE STATEMENT dated October 22, 2003);

Express Mail Mailing Label
No.: EV 842 304 605 US
Date of Deposit: MAY 3, 2006
I hereby certify that this paper is being deposited with the United
States Postal Service "Express Mail
Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to:

MAIL STOP AMENDMENT Commissioner for Patents,

P.O. Box 1450

Alexandria, VA 22313

Dorothy Defrancesco

In the event that this Paper is late filed, and the necessary petition for extension of time is not filed concurrently herewith, please consider this as a Petition for the requisite extension of time, and to the extent not tendered by check attached hereto, authorization to charge the extension fee, or any other fee required in connection with this Paper to Account No. 06-1378.

05/05/2006 EAREGAY1 00000028 10629108

02 FC:1806

180.00 OP

- (4) An English-language abstract of JP 52-102281 (the Japanese language document for JP 52-102281 was submitted with the INFORMATION DISCLOSURE STATEMENT dated October 22, 2003);
- (5) An English-language translation of JP 50-35175 (the Japanese language document for JP 50-35175 was submitted with the INFORMATION DISCLOSURE STATEMENT dated October 22, 2003);
- (6) An English-language translation of JP 57-139066 (the Japanese language document was submitted with the INFORMATION DISCLOSURE STATEMENT dated December 20, 2004); and
  - (7) Forms PTO/SB/08A and PTO/SB/08B.

Form PTO-2038 for the sum of \$180 is attached.

It is respectfully requested that the Examiner return copies of the enclosed Forms PTO/SB/08A and PTO/SB/08B, with the Examiner's initials in the left column next to each cited publication to indicate that the cited publications were considered and made of record.

Respectfully submitted,

Frishauf, Holtz, Goodman & Chick, P.C. 220 Fifth Avenue, 16th Fl.

New York, NY 10001-7708 Tel. Nos. (212) 319-4900

(212) 319-4551/Ext. 219

Richard S. Barth Req. No. 28,180

Fax No.: (212) 319-5101

E-Mail Address: BARTH@FHGC-LAW.COM

RSB/ddf

Enclosures: (1) Forms PTO/SB/08A and PTO/SB/08B and copies of the publications cited therein

(2) Form PTO-2038

sign (+) inside this b	ox → +	PTO/SB/08A (08-00)		
	U.S. Patent and Trademar	c Office: U.S. DEPARTMENT OF COMMERCE		
Form 1449A/PTO	Application Number	10/629,108		
	Filed	July 28, 2003		
DISCLOSURE	First Named Townston	Kazuo KOYAMA		

INTORMATION DISCLOSURE STATEMENT BY APPLICANT

1

MAY 03 2006

Sheet

Substitute for

Group Art Unit

Examiner Name

Dr. Taofiq A. SOLOLA

1626

03338CIP/HG

3 Attorney Docket Number of

#### U.S. PATENT DOCUMENTS

First Named Inventor

Exam. Inits*	Cite No¹	Document Number	Kind Code <sup>2</sup>	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion
	ŀ		a			
						·
				,		
		·				

#### FOREIGN PATENT DOCUMENTS

Exam Inits	Cit e No <sup>1</sup>	Offc³	Document Number4	Kind Code <sup>5</sup>	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion	${f T}^6$
		WO	96/22276	A1	NIPPON SHINYAKU CO., LTD.	07-25-1996		*
		JР	52-102281		TANABE SEIYAKU CO., LTD.	08-27-1977		**
		JР	50-35175		TANABE SEIYAKU CO., LTD.	04-03-1975		*
		JР	57-139066	A	FUJISAWA YAKUHIN KOGYO K.K.	08-27-1982		*
Exami	ner				Date			1

Signature Considered

DATE MAILED: May 3, 2006

EXAMINER: Initial if document considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Place a check here if English translation is attached.

<sup>\*</sup>ENGLISH-LANGUAGE TRANSLATION ENCLOSED;

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

=				· .			10/620 100	7
Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application	on Number	10/629,108			
			Filing Dat	e	July 28, 2003			
			First Name	ed Inventor	Kazuo KOYAMA			
			Group Art	Unit	1626			
					Examiner N	lame	Dr. Taofiq A. SOLOLA	]
Sheet		2	of	3	Attorney D	Oocket Number	03338CIP/HG	
		ОТНЕ	R D	OCUMENTS	- NON-PAT	ENT LITERATU	RE DOCUMENTS	
Examiner Initials <sup>1</sup>	Cite No.1						article, title of item, date, l/or country where published	T²
							al fluid acetylcholinesterase arol., 237, (5) 281-284 (1990).	
		Huntin	gton':	s disease, <u>Eu</u>	ropean Journal		vastigmine in the treatment of e Official Journal of the 00 (2002).	
		DIFRUS	COLO, ive i	M.D., Luigi	Maria SPECCHIO	D, M.D., "Effects of	o SCIRUICCHIO, M.D., Olimpia of rivastigmine on motor and <u>Disorders</u> , 19 (12), 1516-1518	
		DUAN W., GUO Z., JIANG H., ADENHEIM B., XU X., CADET J.L. & MATTSON M.P., "Paroxetine retards disease onset and progression in Huntington's mutant mice, <u>Ann. Neurol.</u> , 55, 5900594, (2004).						
		PAULSEN J. et al., "Depression and Stages of Huntington's Disease, <u>J. Neuropsychiatry</u> <u>Clin. Neurosci.</u> , 17: 496-502 (2005).						
		SPARKS D.L., DANNER F.W., DAVIS. D.G., HACKNEY C., LANDERS T. & COYNE C.M., "Neurochemical and histopathologic characteristic of Pick's disease in a non demented individual", J. Neuropathol. Exp. Neurol., 53(1), 37-42, (1994).						
		PERRY, R.J. and MILLER B.L., "Behavior and Treatment in frontotemperal dementia, Neurology, 56 (Supplement 4) S46-S61, (2001).						
		SWARTZ, J.R., MILLER B.L., LESSER I.M. CARBY AL.L, "Frontoteporal dementia: treatment response to serotonin selective reuptake inhibitors", <u>J. Clin. Psychiatry</u> , 58, 212-216, (1997).						
		INGRAM N.A.W. and NEWGREEN D.B., "The use of tacrine for tardive dyskinesia, Am. J.  Psychiatry, 140, 1629-1631, (1983).						
·		CAROFF S.N. et al., "Treatment of tardive dyskinesia with donepezil, <u>J. Clin.</u> <u>Psychiatry</u> , 62, 128-129, (2001).						
		WINBLAD et al., "Donezepil in patients with severe Alzheimer's disease: double blind, parallel group, placebo controlled study, <u>Lancet</u> , e-pub., March 23, 2006.						
						,		
Examiner Date Considered								

<sup>\*</sup> EXAMINER: Initial if document considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 Place a check here if English translation is attached.

+

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449A/PTO		Application Number	10/629,108						
				Filing Date	July 28, 2003				
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				First Named Inventor	Kazuo KOYAMA				
	STATEMENT BY APPLICANT			Group Art Unit	1626				
				Examiner Name	Dr. Taofiq A. SOLOLA				
Sheet	3	of	3	Attorney Docket Number	03338CIP/HG				
	ОТНЕ	ER D	OCUMENTS	- NON-PATENT LITERATU	JRE DOCUMENTS				
Examiner Cite Initials No. 1				(in CAPITAL LETTERS), title of e number(s), publisher, city an					
				.J., Biological Therapies for Oractice, 113-128, May 2000.	bsessive-Compulsive Disorders",				
	SHEEHA	N, D.	V., "The Mana , 17-21.	gement of Panic Disorder", J. C	lin. Psychiatry, 2002, 63				
	FERNAN	DEZ H	. and FRIEDMA	N J., "Donezepil for Huntington	's Disease", <u>Movement</u>				
	Disord	<u>Disorders</u> , 15, 173-176, 2000.							
Examiner Signature				Date Considered					

<sup>\*</sup> EXAMINER: Initial if document considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE	MAILED:	May 3,	2006	

 $<sup>^{1}</sup>$  Unique citation designation number.  $^{2}$  Place a check here if English translation is attached.